SL 0101-1

• UNSPSC Description:

  SL 0101-1 (SL0101), a kaempferol glycoside, isolated from the tropical plant F. refracta, is a cell-permeable, selective, reversible, ATP-competitive p90 Ribosomal S6 Kinase (RSK) inhibitor, with an IC50 of 89 nM[1]. SL 0101-1 (SL0101) is a selective RSK1/2 inhibitor, with a Ki of 1 μM[2].

• Target Antigen:

  Ribosomal S6 Kinase (RSK)

• Type:

  Natural Products

• Related Pathways:

  MAPK/ERK Pathway

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/SL_0101-1.html

• Solubility:

  DMSO : 10 mg/mL (ultrasonic;warming)

• Smiles:

  OC1=CC(O)=C(C(C(O[C@@H]2O[C@@H](C)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H]2O)=C(C3=CC=C(O)C=C3)O4)=O)C4=C1

• Molecular Weight:

  516.45

• References & Citations:

  [1]Smith JA, et al. Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation. Cancer Res. 2005 Feb 1;65(3):1027-34.|[2]Yu Li, et al. The Affinity of RSK for Cylitol Analogues of SL0101 Is Critically Dependent on the B-ring C-4'-hydroxy. Chem Commun (Camb). 2020 Mar 10;56(20):3058-3060.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  77307-50-7